赵, 丰 – page 9 – eisai china lnc.-爱游戏app官网入口

shanghai tenry pharmaceutical company limited (hereinafter referred to as “shanghai tenry”) and eisai china inc. signed a marketing service agreement. shanghai tengry is responsible for the market promotion of glufast® (mitiglinide calcium tablets), a diabetes treatment drug, in china, and the two parties will work hand in hand to serve the vast population of diabetic patients in china.

tokyo and new york, june 18, 2021 — eisai co., ltd. and bristol-myers squibb company (nyse: bmy) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of morab-202, an antibody drug conjugate (adc). morab-202 is eisai’s first adc and combines eisai’s in house developed anti-folate receptor alpha (frα) antibody, and eisai’s anticancer agent eribulin, using an enzyme cleavable linker. it is a potential best-in-class frα adc with a favorable pharmacology profile and demonstrated single agent activity in patients with advanced solid tumors. eisai is currently investigating morab-202 in frα-positive solid tumors (inclusive of endometrial, ovarian, lung and breast cancers) in two studies: a phase 1 clinical study in japan and a phase 1/2 clinical study in the united states. the companies are planning to move into the registrational stage of development for this asset as early as next year.